9 Meters Biopharma Inc (NMTR)
NASDAQ (CM) NASDAQ (CM) Primary Summary
9 Meters Biopharma Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 162.5 | $254,462 | $11.73 | -$254,450.27 | -100% |
9 Meters Biopharma Inc (NMTR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has 9 Meters Biopharma Inc ever had a stock split?
9 Meters Biopharma Inc Profile
| Biotechnology Industry | Healthcare Sector | Peter H. R. Green CEO | NASDAQ (CM) Exchange | 654405208 CUSIP |
| US Country | 10 Employees | 28 Jun 2024 Last Dividend | 9 Mar 2023 Last Split | - IPO Date |
Overview
9 Meters Biopharma, Inc. was a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for individuals suffering from rare digestive diseases and gastrointestinal conditions that lacked adequate therapeutic options. Based in Raleigh, North Carolina, the company aimed to address the unmet needs of patients across North America by focusing on debilitating disorders that impact quality of life. Despite its ambitious mission and a pipeline of promising drug candidates, 9 Meters Biopharma, Inc. encountered significant challenges that led to the filing of a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina on July 17, 2023. This move marked the end of its endeavor to bring novel therapies to the market.
Products and Services
- Vurolenatide
- NM-136
- NM-102
- NM-003
- Larazotide
A flagship product candidate, Vurolenatide, is a long-acting injectable glucagon-like-peptide-1 (GLP-1) that was in Phase 3 clinical trial for the treatment of short bowel syndrome. This condition leads to malabsorption and numerous health issues due to the inability to absorb nutrients adequately.
9 Meters was developing NM-136, a humanized monoclonal antibody aimed at treating obesity and obesity-related disorders. This innovative approach represented the company’s commitment to addressing widespread health concerns with novel biotechnological methods.
NM-102, a small molecule peptide, was designed to prevent antigens from reaching systemic circulation. This preventative approach aimed at mitigating immune responses that could lead to or exacerbate gastrointestinal conditions.
Another proprietary development, NM-003, was a long-acting glucagon-like peptide-2 receptor agonist intended for the prevention of acute graft versus host disease (GVHD), showcasing 9 Meters’ focus on critical needs in transplant medicine.
In collaboration with partners, 9 Meters was involved in the development of Larazotide, an 8-amino acid peptide undergoing a Phase 2 clinical trial for the treatment of multi-system inflammatory syndrome. This effort was indicative of the company’s broader mission to tackle complex immune and inflammatory conditions.
